Evidence map›Paper›PMID 27732946›Full record

ArticleOncotarget2016

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.

Min Huang, Jacqueline S Garcia, Daniel Thomas, Li Zhu, Le Xuan Truong Nguyen, Steven M Chan, Ravindra Majeti, Bruno C Medeiros, Beverly S Mitchell

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Min HuangStanford Cancer Institute, Stanford University, Stanford, California, USA.
Jacqueline S GarciaDivision of Hematology, Department of Medicine, Stanford University, Stanford, California, USA.
Daniel ThomasDivision of Hematology, Department of Medicine, Stanford University, Stanford, California, USA.
Li ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Le Xuan Truong NguyenStanford Cancer Institute, Stanford University, Stanford, California, USA.
Steven M ChanDivision of Hematology, Department of Medicine, Stanford University, Stanford, California, USA.
Ravindra MajetiStanford Cancer Institute, Stanford University, Stanford, California, USA.
Bruno C MedeirosStanford Cancer Institute, Stanford University, Stanford, California, USA.
Beverly S MitchellStanford Cancer Institute, Stanford University, Stanford, California, USA.
Stanford University · USCalifornia Institute for Regenerative Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

The mechanisms underlying activation of the BET pathway in AML cells remain poorly understood. We have discovered that autophagy is activated in acute leukemia cells expressing mutant nucleophosmin 1 (NPMc+) or MLL-fusion proteins. Autophagy activation results in the degradation of NPM1 and HEXIM1, two negative regulators of BET pathway activation. Inhibition of autophagy with pharmacologic inhibitors or through knocking down autophagy-related gene 5 (Atg5) expression increases the expression of both NPM1 and HEXIM1. The Brd4 inhibitors JQ1 and I-BET-151 also inhibit autophagy and increase NPM1 and HEXIM1 expression. We conclude that the degradation of NPM1 and HEXIM1 through autophagy in certain AML subsets contributes to the activation of the BET pathway in these cells.

Indexed as

AutophagyBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorCell ProliferationGene Expression Regulation, LeukemicHumansLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinNuclear ProteinsNucleophosminOncogene Proteins, FusionProteinsProtein TransportProteolysisRNA-Binding ProteinsBRD4 protein, humanbromodomain and extra-terminal domain protein, humanBromodomain Containing ProteinsCell Cycle ProteinsHEXIM1 protein, humanMyeloid-Lymphoid Leukemia ProteinNPM1 protein, humanNuclear ProteinsNucleophosminOncogene Proteins, FusionProteinsRNA-Binding ProteinsTranscription FactorsAMLautophagyBET inhibitorsHEXIM1NPM1

Identifiers

PMID27732946
PMCPMC5342712
OpenAlexW2528553701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.